Good science alone does not create company value. Investors and partners ask three questions early. How large is the market for your chosen indication? What will it cost to get there? How far must the project go before it can be financed or partnered? Too often, willingness to pay and market validation are left until it’s too late.
At this breakfast seminar, a SwedenBIO Insight seminar organised by SwedenBIO’s Business Strategy group, life science leaders take you through three key steps using real company cases:
- choosing the right entry indication
- understanding who will pay for your product
- having your product evaluated by people outside the company
We’ll share the decisions that increased the value of their companies, and the lessons learned along the way. Speakers include Jens Lindberg, CEO of Medivir, Sofia Heigis, CEO of Oncopeptides, and Jimmie Hofman, CBO of Vicore Pharma.
You’ll leave with one or two concrete actions you can apply to your own development plan, and time to talk them over with peers afterwards.
More info and Register here
